

8-K Filed February 11, 2010



Introduction

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results will be included in the Company's Form 10-K for the year ended December 31, 2009, and subsequent SEC filings. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.



Fourth Quarter Results

(In millions, except per share data)

	Three Months		
	2009	2008	+/(-)
Adjusted Revenue ⁽¹⁾	\$ 1,165.1	\$ 1,126.6	3.4%
Adjusted Operating Income ⁽¹⁾	\$ 221.9	\$ 219.8	1.0%
Adjusted Operating Income Margin ⁽¹⁾	19.0%	19.5%	(50) bp
Adjusted EPS ⁽¹⁾	\$ 1.16	\$ 1.10	5.5%
Operating Cash Flow	\$ 224.7	\$ 215.3	4.4%
Less: Capital Expenditures	<u>\$ (37.6)</u>	<u>\$ (36.3)</u>	<u>3.6%</u>
Free Cash Flow	\$ 187.1	\$ 179.0	4.5%

(1) See Reconciliation of non-GAAP Financial Measures (included herein)



Full Year Results (In millions, except per share data)

	Year Ende		
	2009	2008	+/(-)
Adjusted Revenue ⁽¹⁾	\$ 4,694.7	\$ 4,512.7	4.0%
Adjusted Operating Income ⁽¹⁾	\$ 954.9	\$ 937.0	1.9%
Adjusted Operating Income Margin ⁽¹⁾	20.3%	20.8%	(50) bp
Adjusted EPS ⁽¹⁾	\$ 4.89	\$ 4.60	6.3%
Operating Cash Flow	\$ 862.4	\$ 780.9	10.4%
Less: Capital Expenditures	<u>\$ (114.7)</u>	<u>\$ (156.7)</u>	<u>-26.8%</u>
Free Cash Flow	\$ 747.7	\$ 624.2	19.8%


(1) See Reconciliation of non-GAAP Financial Measures (included herein)






Cash Flow Trends

11% OCF CAGR 2004-2009






Revenue by Payer- US 2009 YTD





Revenue by Business Area - US 2009 YTD







	YTD Q4-2007				YTD Q	4-2008 ⁽¹⁾		YTD Q4-2009				
	Revenue			Revenue				Revenue				
	\$'s	%	Accns	PPA	\$'s	%	Accns	PPA	\$'s	%	Accns	PPA
Client	\$1,081.1	27%	34.213	\$ 31.60	\$1,195.3	28%	35.521	\$ 33.65	\$1,207.4	27%	34.802	\$ 34.69
Patient	367.7	9%	2.315	\$158.84	369.6	9%	2.240	\$165.00	337.6	8%	2.087	\$161.76
Third Party (Medicare/Medicaid)	745.8	18%	18.343	\$ 40.66	803.1	19%	18.939	\$ 42.40	896.4	20%	19.645	\$ 45.63
Managed Care:												
- Capitated	167.4	4%	14.962	\$ 11.19	180.0	4%	15.227	\$ 11.82	167.4	4%	15.055	\$ 11.12
- Fee for service	1,706.2	42%	37.462	\$ 45.54	1,715.7	40%	37.725	\$ 45.48	1,838.5	41%	38.828	\$ 47.35
Total Managed Care	1,873.6	46%	52.424	\$ 35.74	1,895.7	44%	52.952	\$ 35.80	2,005.8	45%	53.883	\$ 37.23
LabCorp Total - US	\$4,068.2	100%	107.295	\$ 37.92	\$4,263.7	100%	109.652	\$ 38.88	\$4,447.2	100%	110.417	\$ 40.28
LabCorp Total - Canada	\$ -	-	-	-	\$ 249.0		8.052	\$ 30.92	\$ 247.5		9.088	\$ 27.23
LabCorp Total	\$4,068.2		107.295	\$ 37.92	\$4,512.7		117.704	\$ 38.34	\$4,694.7		119.505	\$ 39.28

(1) Excludes a cumulative revenue adjustment of \$7.5 million recorded by the Company in the fourth quarter of 2008



Revenue by Business Area (in millions, except PPA)

		YTD Q4-2007					YTD Q4-2008 ⁽¹⁾						YTD Q4-2009						
			Revenu	e					Revenu	e					Revenu	ie			
			\$'s	%	Accns		PPA		\$'s	%	Accns		PPA		\$'s	%	Accns]	PPA
	All Genomic	\$	629.6	15%	8.452	\$	74.50	\$	654.8	15%	8.843	\$	74.05	\$	697.9	16%	9.117	\$	76.55
•	Other Esoteric		441.6	11%	10.775		40.99		510.1	12%	12.232		41.70		608.0	14%	14.223		42.75
]	Histology		325.1	8%	2.675		121.51		321.0	8%	2.583		124.26		295.6	6%	2.433		121.50
	All Genomic / Esoteric		1,396.3	34%	21.902		63.76		1,485.8	35%	23.658		62.80		1,601.6	36%	25.773		62.14
	Core		2,671.9	66%	85.393		31.29		2,777.9	65%	85.994		32.30		2,845.6	64%	84.644		33.62
]	LabCorp Total - US	\$	4,068.2	100%	107.295	\$	37.92	\$	4,263.7	100%	109.652	\$	38.88	\$	4,447.2	100%	110.417	\$	40.28
]	LabCorp Total - Canada	\$	-	-	-		-	\$	249.0		8.052	\$	30.92	\$	247.5		9.088	\$	27.23
	LabCorp Total	\$	4,068.2	100%	107.295	\$	37.92	\$	4,512.7		117.704	\$	38.34	\$	4,694.7		119.505	\$	39.28

(1) Excludes a cumulative revenue adjustment of \$7.5 million recorded by the Company in the fourth quarter of 2008



Financial Guidance - 2010

Excluding the impact of restructuring and other special charges and share repurchase activity after December 31, 2009, guidance for 2010 is:

• Revenue growth:	Approximately 2.5% – 4.5%
• Adjusted EPS:	\$5.35 to \$5.55
• Operating cash flow of approximately ⁽¹⁾ :	\$870 Million
Capital expenditures of approximately:	\$135 Million

(1) Operating cash flow guidance excludes any transition payments to UnitedHealthcare.



Supplemental Financial Information

Laboratory Corporation of America Other Financial Information December 31, 2009

(\$ in million's)

					YID
	Q1 09	Q2 09	Q3 09	Q4 09	2009
Depreciation	\$31.8	\$32.9	\$33.1	\$32.9	\$130.7
Amortization	\$15.1	\$15.2	\$15.9	\$16.4	\$62.6
Capital expenditures	\$30.7	\$23.7	\$22.7	\$37.6	\$114.7
Cash flows from operations	\$208.9	\$182.4	\$246.4	\$224.7	\$862.4
Bad debt as a percentage of sales	5.3%	5.3%	5.3%	5.3%	5.3%
Effective interest rates on debt:					
Zero-coupon subordinated notes	2.00%	2.00%	2.00%	2.00%	2.00%
5 1/2% Senior Notes	5.38%	5.38%	5.38%	5.38%	5.38%
5 5/8% Senior Notes	5.75%	5.75%	5.75%	5.75%	5.75%
Term loan	3.67%	3.67%	3.67%	3.67%	3.67%
Revolving credit facility (weighted average)	0.97%	0.76%	0.70%	0.58%	0.58%
Days sales outstanding	52	50	48	44	44
UnitedHeathcare transition payments - Billed	\$5.5	\$12.4	\$9.5	\$6.7	\$34.1
UnitedHeathcare transition payments - Paid	\$5.5	\$10.5	\$8.5	\$3.9	\$28.4



VTD

Reconciliation of non-GAAP Financial Measures

Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	Three Months 1	Ended Dec 31,		
Adjusted Revenue	2009	2008		
Revenue	\$1,165.1	\$1,119.1		
Cumulative revenue adjustment (1)		7.5		
Adjusted revenue	\$1,165.1	\$1,126.6		
Adjusted Operating Income				
Operating income	\$215.8	\$204.4		
Restructuring and other special charges (1)	6.1	15.4		
Adjusted operating income	\$221.9	\$219.8		
Adjusted EPS				
Diluted earnings per common share	\$1.33	\$1.08		
Impact of restructuring and other special charges (1) (2) (3)	(0.17)	0.02		
Adjusted EPS	\$1.16	\$1.10		

(1) 2009 includes net restructuring charges of \$3.3 million (\$2.0 million after tax), and a one-time charge of \$2.8 million (\$17 million after tax) for curtailment of employee and executive pension plans. 2008 includes net restructuring charges of \$4.2 million (\$2.5 million after tax), \$3.7 million (\$2.2 million after tax) of accelerated stock compensation relating to Executive Vice President retirement, and a \$7.5 million (\$4.5 million after tax) cumulative revenue adjustment relating to certain historic overpayments made by Medicare for claims submitted by a subsidiary of the Company.

(2) In 2009, the Company recorded favorable adjustments of \$215 million to its fourth quarter tax provision relating to the resolution of certain state tax is sues under audit, as well as the realization of foreign tax credits. In 2008, the Company recorded a 7.1 million reduction to its fourth quarter tax provision as a result of tax treaty amendments with Canada. These adjustments had no impact on operating income, but did increase net earnings by 215 million and 7.1 million, respectively.

(3) 2009: \$17.8 million divided by 107.5 million shares

2008: \$2.1 million divided by 109.5 million shares



Reconciliation of non-GAAP Financial Measures

Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	Year Endec	l Dec 31,
Adjusted Revenue	2009	2008
Revenue	\$4,694.7	\$4,505.2
Cumulative revenue adjustment (1)		7.5
Adjusted Revenue	\$4,694.7	\$4,512.7
Adjusted Operating Income		
Operating income	\$935.9	\$842.9
Restructuring and other special charges (1)	19.0	94.1
Adjusted operating income	\$954.9	\$937.0
Adjusted EPS		
Diluted earnings per common share	\$4.98	\$4.16
Impact of restructuring and other special charges (1) (2) (3)	(0.09)	0.44
Adjusted EPS	\$4.89	\$4.60

(1) 2009 includes net restructuring charges of \$13.5 million (\$8.1 million after tax), a one-time charge of \$2.8 million (\$1.7 million after tax) for curtailment of employee and executive pension plans, and \$2.7 million (\$1.6 million after tax) trans action fees and expenses associated with the acquisition of Monogram Biosciences. 2008 includes net restructuring charges of \$37.9 million (\$2.9 million after tax), \$3.7 million (\$2.2 million after tax) of accelerated stock compensation relating to Executive Vice President retirement, and a \$7.5 million (\$4.5 million after tax) cumulative revenue adjustment relating to certain historic overpayments made by Medicare for claims submitted by a subsidiary of the Company. In the second quarter of 2008, the Company increased its allowance for doubtful accounts by \$45 million (\$27.3 million after tax) due to impact of the economy, higher patient deductibles and co-payments on the collectability of accounts receivable balances.

(2) In 2009, the Company recorded favorable adjustments of \$21.5 million to its fourth quarter tax provision relating to the resolution of certain state tax is sues under audit, as well as the realization of foreign tax credits. In 2008, the Company recorded a \$7.1 million reduction to its fourth quarter tax provision as a result of tax treaty amendments with Canada. These adjustments had no impact on operating income, but did increase net earnings by \$21.5 million and \$7.1 million, respectively.

(3) 2009: \$10.1 million divided by 109.1 million shares

2008: \$49.8 million divided by 111.8 million shares

